Toll Free: 1-888-928-9744

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Corcept Therapeutics Incorporated - Product Pipeline Review - 2014', provides an overview of the Corcept Therapeutics Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Corcept Therapeutics Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Corcept Therapeutics Incorporated including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Corcept Therapeutics Incorporated's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Corcept Therapeutics Incorporated's pipeline products

Reasons to buy

- Evaluate Corcept Therapeutics Incorporated's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Corcept Therapeutics Incorporated in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Corcept Therapeutics Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Corcept Therapeutics Incorporated and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Corcept Therapeutics Incorporated
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Corcept Therapeutics Incorporated and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Corcept Therapeutics Incorporated Snapshot 4
Corcept Therapeutics Incorporated Overview 4
Key Information 4
Key Facts 4
Corcept Therapeutics Incorporated - Research and Development Overview 5
Key Therapeutic Areas 5
Corcept Therapeutics Incorporated - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Corcept Therapeutics Incorporated - Pipeline Products Glance 9
Corcept Therapeutics Incorporated - Late Stage Pipeline Products 9
Pre-Registration Products/Combination Treatment Modalities 9
Phase III Products/Combination Treatment Modalities 10
Corcept Therapeutics Incorporated - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Corcept Therapeutics Incorporated - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Corcept Therapeutics Incorporated - Drug Profiles 13
mifepristone 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
CORT-113083 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Selective Glucocorticoid Receptor-II Antagonists 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Corcept Therapeutics Incorporated - Pipeline Analysis 18
Corcept Therapeutics Incorporated - Pipeline Products by Target 18
Corcept Therapeutics Incorporated - Pipeline Products by Route of Administration 19
Corcept Therapeutics Incorporated - Pipeline Products by Molecule Type 20
Corcept Therapeutics Incorporated - Pipeline Products by Mechanism of Action 21
Corcept Therapeutics Incorporated - Recent Pipeline Updates 22
Corcept Therapeutics Incorporated - Dormant Projects 26
Corcept Therapeutics Incorporated - Company Statement 27
Corcept Therapeutics Incorporated - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Corcept Therapeutics Incorporated, Key Information 4
Corcept Therapeutics Incorporated, Key Facts 4
Corcept Therapeutics Incorporated - Pipeline by Indication, 2014 6
Corcept Therapeutics Incorporated - Pipeline by Stage of Development, 2014 7
Corcept Therapeutics Incorporated - Monotherapy Products in Pipeline, 2014 8
Corcept Therapeutics Incorporated - Pre-Registration, 2014 9
Corcept Therapeutics Incorporated - Phase III, 2014 10
Corcept Therapeutics Incorporated - Phase I, 2014 11
Corcept Therapeutics Incorporated - Preclinical, 2014 12
Corcept Therapeutics Incorporated - Pipeline by Target, 2014 18
Corcept Therapeutics Incorporated - Pipeline by Route of Administration, 2014 19
Corcept Therapeutics Incorporated - Pipeline by Molecule Type, 2014 20
Corcept Therapeutics Incorporated - Pipeline Products by Mechanism of Action, 2014 21
Corcept Therapeutics Incorporated - Recent Pipeline Updates, 2014 22
Corcept Therapeutics Incorporated - Dormant Developmental Projects,2014 26 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify